Volume 4 Supplement 2

Current perspectives on the treatment of rheumatic diseases with infliximab


Edited by Peter E Lipsky and Ravinder N Maini

Supported by an educational grant from Centocor, Inc.

  1. Supplement

    Current and future management approaches for rheumatoid arthritis

    With the introduction of new disease-modifying antirheumatic drugs (DMARDs) and other therapeutic agents, the management of rheumatoid arthritis (RA) has shifted toward earlier, more aggressive therapy. The ul...

    Ferdinand C Breedveld

    Arthritis Research & Therapy 2002 4(Suppl 2):S16

    Published on: 27 March 2002

  2. Supplement

    How does infliximab work in rheumatoid arthritis?

    Since the initial characterization of tumor necrosis factor alpha (TNFα), it has become clear that TNFα has diverse biologic activity. The realization that TNFα plays a role in rheumatoid arthritis (RA) has le...

    Ravinder N Maini and Marc Feldmann

    Arthritis Research & Therapy 2002 4(Suppl 2):S22

    Published on: 27 March 2002

  3. Supplement

    Autoantibodies in rheumatoid arthritis and their clinical significance

    Autoantibodies are proven useful diagnostic tools for a variety of rheumatic and non-rheumatic autoimmune disorders. However, a highly specific marker autoantibody for rheumatoid arthritis (RA) has not yet bee...

    Günter Steiner and Josef Smolen

    Arthritis Research & Therapy 2002 4(Suppl 2):S1

    Published on: 26 April 2002